

In Silico Investigation of Phytoconstituents from Indian Medicinal Herb ‘*Tinospora Cordifolia* (Giloy)’ as Potential Inhibitors against SARS-CoV-2 (COVID-19)

Papia Chowdhury *

Department of Physics and Materials Science and Engineering,
Jaypee Institute of Information Technology, Noida 201309, Uttar Pradesh, India.

*Corresponding author: papia.chowdhury@jiit.ac.in

Abstract:

The recent appearance of COVID-19 virus has created a global crisis due to unavailability of any vaccine or drug that can effectively and deterministically work against it. Naturally, different possibilities (including herbal medicines having known therapeutic significance) have been explored by the scientists. The systematic scientific study (beginning with in silico study) of herbal medicines in particular and any drug in general is now possible as the structural components (proteins) of COVID-19 are already characterized. The identified protein structures showed that the main protease of COVID-19 virus is M^{pro} or 3CL^{pro} which is a key CoV enzyme and an attractive drug target as it plays a pivotal role in mediating viral replication and transcription. In the present study structure of 3CL^{pro} is used to study drug:3CL^{pro} interactions and thus to investigate whether all or any of the main chemical constituents of *Tinospora cordifolia* (e.g., berberine (C₂₀H₁₈NO₄), β-sitosterol (C₂₉H₅₀O), coline (C₅H₁₄NO), tetrahydropalmatine (C₂₁H₂₅NO₄) and octacosanol (C₂₈H₅₈O)) can be used as an anti-viral drug against SARS-CoV-2. The in silico study performed using tools of network pharmacology and molecular docking has revealed that the above mentioned phytochemicals available in *Tinospora cordifolia* can regulate 3CL^{pro} protein's function and thus control viral replication. The selection of *Tinospora cordifolia* was motivated by the fact that the main constituents of it are known to be responsible for various antiviral activities and the treatment of jaundice, rheumatism, diabetes, etc.

Keywords: COVID-19, SARS-CoV-2, *Tinospora cordifolia*, berberine, 3CL^{pro}, β-sitosterol

1. Introduction:

In 2020, with the outbreak of a newly detected corona virus, the whole world is witnessing a pandemic situation which has put human life in crisis as more than 364400 people have already died due to this virus in last couple of months. Coronaviruses belong to a large family of viruses which may cause illness in animals and human. In human, these viruses can cause different types of respiratory infections such as common cold, Middle East Respiratory Syndrome (MERS) and Severe Acute Respiratory Syndrome (SARS) [1]. Coronavirus disease COVID-19 is the most recently declared disease by WHO caused by a new member “novel coronavirus” of this virus family [2]. This new virus and disease were unknown before its outbreak began in Wuhan, China, in late December 2019 [3,4]. On 11 February 2020, the international committee on taxonomy of viruses declared the new novel coronavirus as “severe acute respiratory syndrome coronavirus 2” (SARS-CoV-2) [5] (originally tentatively named 2019-nCoV). SARS-CoV-2 is part of the Coronaviridae family of virus SARS-CoV with a genome sequences of 79.5% sequence matching. The members of this family are named after their crown-like appearance under the electron microscope caused by the surface glycoproteins that decorate the virus. The critical part of SARS-CoV-2 is its spike protein. It recognizes a human protein that coats the insides of the nose and the cells of our lungs and interact with them. When the two proteins bind, the spike protein changes shape, which causes the cell to engulf the virus. It can then replicate, infect neighboring cells and tissues, and seriously damage the lung and many other organs. Only a few weeks after the virus appeared, its structural components (proteins) were characterized, giving the first insights on how the virus works and how we can fight against it. By now, structural biologists have determined more than 160 structures of nine different viral SERS CoV 2 proteins by X-ray crystallography. The spike protein, which protrudes from the lipid shell of the virus, is the principal target of vaccine or drug to act on. If the human immune system were primed to recognize and counteract the spike protein, the infectivity of the virus would be much reduced and maybe even eliminated. COVID-19 has now become a pandemic worldwide affecting mostly all countries globally. It is an infectious disease with a high potential for transmission to close contacts through the respiratory droplets (such as coughing) and by fomites that can propagate through air at a minimum distance of 1 meter [6, 7]. Research performed till now suggests that maintaining a distance of more than 1 meter between two individuals which is termed as ‘social distancing’/’physical distancing’ along with proper hand-hygiene reduces the chance of being infected by COVID-19. Though there are many predictions about the airborne transmission of this disease, but until now no scientifically valid evidence is available [8]. The most common symptoms of COVID-19 are fever, dry cough, and tiredness.

These symptoms are usually mild and begin gradually. Some infected people become asymptomatic or only have very mild symptoms. The main point of concern is that at present, no specific therapies for COVID-19 are available and research regarding the treatment of COVID-19 are in infancy. As per current data of May 30th, 2020, over 58,05000 cases of COVID-19 have been confirmed worldwide, over 3,64239 of which have resulted in death. The supportive care and non-specific treatment to ameliorate the symptoms of the patient are the only options currently. However, extensive research leading to clinical trials of both western and traditional medicines are going on to develop vaccines and medicines to prevent and treat COVID-19 [9].

To combat COVID-19, some preliminary research observations have indicated that the combinations of some clinically applied anti-malarial drugs (e.g., chloroquine, hydroxychloroquine) and anti-HIV vaccines can be used to treat CoV-2 infections. Also some conventional drugs (remdesivir, nelfinavir, pitavastatin, perampanel, praziquantel, etc.) have been tried as the potential inhibitor against SARS-CoV-2 and found with certain curative effect *in vitro* [10, 11]. None of the clinically applied drug/vaccine response is found to be very encouraging till now. Also toxicity of the drugs remain an inevitable issue causing serious adverse effects to the patients [12]. In short, to the best of our knowledge, no specific therapy and medicine for the effective treatment of COVID-19 has yet been reported. This unavailability of cure to this disease motivated me to investigate the possibility of inhibition of CoV-2 by some phytoconstituents available from some Indian medicinal plants. Medicinal herb extracts have accumulated thousand-of-year's experiences in the treatment of pandemic and endemic diseases. Since providing complementary and alternative treatments are still urgently needed for the management of patients with SARS-CoV-2 infection, research works with different phytoconstituents from various traditional medicinal herbs is certainly worth of investigation. For the present work, we have chosen an Indian medicinal plant: Guduchi Pippali (Giloy) or *Tinospora cordifolia* (Figure 1). It belongs to the family of Menispermaceae and is found in India, Myanmar, Sri Lanka, and China. The plant is commonly used in traditional Ayurvedic medicine and has several therapeutic properties against jaundice, rheumatism, urinary disorder, skin diseases, diabetes, anemia, inflammation, allergic condition, etc. [13]. The stem of the plant is useful in the treatment of helminthiasis, heart diseases, leprosy, rheumatoid arthritis, etc. It supports the immune system by increasing the body's resistance to various infections, supports standard white blood cell structure, function, and levels [14]. The above mentioned pharmacological activities of the plant originates from its chemical constituents of different classes such as alkaloids, glycosides, steroids, phenolics, aliphatic compounds, polysaccharides essential oils, a mixture of fatty acids, and

polysaccharides which are present in a different part of the plant body, including root and stem. Phytochemistry of all these are well documented in the literature [14]. Estimation of pharmacological properties of small molecules when it interacts with target protein is considered as a crucial step towards the drug discovery. We have selected a few phytoconstituents extracted compounds from *Tinospora cordifolia* (Figure 2). These phytoconstituents were selected after applying the proper virtual screening of drug-likeness rules which are set of guidelines for the structural properties of potential drug compounds, used for fast calculation of drug-like properties of a molecule. After virtual screening, we have evaluated their potential inhibition properties against CoV-2 main protease *in silico* by the mechanism of molecular docking. Due to the fact that *in vivo* estimation of drug molecules is time consuming and expensive, *in silico* methods have become inevitable as we need an urgent solution of the present crisis. Information of chemical constituent activities has allowed the research community to explore computational molecular docking methods for investigating the drug-protein interactions. Variety of simulation methods and databases have yet been used for the *in-silico* prediction of target drugs [15,16]. Many groups are presently working on different quantum mechanical simulation techniques to search varieties of interacted complex configurations of different organic and inorganic systems and their interactions with different environments [17]. We have earlier studied the environmental effects on different organic probe molecules in view of their applications in various biomedical field [18]. In the presented study, we have reported some encouraging responses we obtained in terms of inhibition potentials from some of the tested phytoconstituents of current probe system: *Tinospora cordifolia*. We believe that the results of the present study will lead to some important insights into the development of alternative drugs for COVID-19.

2. Materials and Methods:

2.1. Potential Target Protein Structures for SARS-CoV-2

Coronaviruses have positive-sense single-stranded RNA. SARS-CoV-2 belongs to the β -coronavirus genus [19]. It has a genome size of ~30 kilobases and encodes for multiple structural and non-structural proteins. The structural proteins include: spike (S), envelope (E), membrane (M), and nucleocapsid (N). Structure of SARS-CoV-2 has been identified quickly, and its genomic sequence is already available [3,4]. Since the virus has been discovered very recently so very few available immunological information (immunogenic epitopes eliciting antibody or T cell responses) about the virus are available until now. Until now, no therapeutics or vaccines are approved against any human-infecting coronaviruses. SARS-CoV-2 is closely related to the known SARS-CoV structures which allows

utilization of this known protein structures to quickly build a model for discovery drugs against this newly appeared virus [3]. It is reported very recently that CoV-2 enters into host cells by the spike (S) glycoprotein that forms homotrimers protruding from the viral surface [20]. This spike protein interacts strongly with the human ACE2 (angiotensin-converting enzyme 2) receptor [21]. After entering the host cell, SARS-CoV-2 replicates itself through some cyclic processes. First it translates its genomic RNA (gRNA), then proteolysis of the translated polyprotein takes place with viral 3C-like proteinase, after that replication of gRNA with the viral replication complex happens which consists of RNA dependent RNA polymerase (RdRp), helicase, 30-to-50 exonuclease, endoRNase, and 20-O-ribose methyltransferase; and lastly assembly of viral components takes place. These proteins (S) which are associated with replication are the primary targets of post-entry treatment drugs or vaccine design to suppress viral replication/infection or neutralizing antibodies (Abs) upon infection [21, 22]. SARS-CoV-2 3C like proteinase is already predicted to bind with different FDA approved antiviral commercially available drugs like atazanavir, remdesivir, efavirenz, ritonavir, lopinavir and other antiviral drugs that have a predicted affinity of having efficacy value $K_d > 100$ nM potency [23]. Prediction suggests that viral proteinase-targeting drugs were predicted to act more favorably on the viral replication process. For example, a docking study of lopinavir along with other HIV proteinase inhibitors of the CoV proteinase suggests atazanavir and ritonavir may inhibit the CoV proteinase in line with the inhibitory potency of lopinavir [23]. Though some case studies are available, until now there is no real evidence about whether these drugs will act as predicted against COVID-19. Traditional drug discovery usually takes years of research and trial. Now the whole world is dealing with an emergency situation with an urgent need of required drug against this virus to save the infected lives. An alternative approach to combat this problem and to complement the existing procedure is to use the computer-assisted structure-based drug design (SBDD) or the computer-aided drug design (CADD). In the present work, we have used a particular type of SBDD approach. Specifically, we tried here the *in silico* docking model approach to search for medication of COVID-19 by using two most variable viral proteins (I, II) SARS-CoV-2 protease enzyme M^{pro} or 3CL^{pro} as the receptor (Figure 3a,b).

3CL^{pro} is a key to SERS-CoV enzyme. CoV 3CL^{pro} is responsible for the maturation of itself and the subsequent maturation of the replicate polyproteins. This protein has a highly conserved catalytic domain from the SARS virus and is responsible for controlling several major functions of the virus like the replication and transcription processes of the virus which makes it an ideal target for drug development [24]. The functional importance of 3CL^{pro} in the viral life cycle, together with the absence of closely

related homologues in human creates the 3CL^{pro} as an attractive target for antiviral drug design. Recently 3D structure of one 3C like protease protein is unveiled by X-Ray crystallography (PDBID: 6LU7) [25]. Protease proteins are essential to the transmission and virulence of the virus. For a higher active therapy, by inhibiting these the severity of the infection will definitely be reduced. In the present work, we have tried to check the inhibiting and binding possibilities of two of these natural substrates in order to find the possibilities of effective drug design.

2.2 Protein Receptors Preparation

In this work we have used two CoV-2 3CL^{pro} main proteases as target of the potential drug molecules. The proteases used are: protease in complex with an inhibitor N3 (PDBID: 6LU7) [25] referred to as I and the other one is protease bound to potent broad-spectrum non-covalent inhibitor X77 (PDBID: 6W63) referred to as II [26]. The 3D structures of both were downloaded from the Protein Data Bank [27] and are shown in (Figure 3a,b) without added water and hydrogen. All the available required properties are described in Table 1. At the beginning of the present investigation, we cleaned all the protein structures by removing the existing lead components, water molecules and ions. Then we computed Gasteiger charges with inclusion of polar hydrogens. Merging of non-polar and rotatable bonds were subsequently defined using Auto Dock and MG Tools of Auto DockVina software [28]. Lastly the in build ligands were removed from the protein molecules using Discovery studio 2020 [29]. Structures of the proteins were saved in PDB format for further analysis. Active amino acid residues which will be involved in mediating enzyme activity for protein-ligand interaction were predicted for each target protein using Ramachandran plot (Figure 3b) which provides a way to visualize dihedral angles ψ against ϕ of amino acid residues in protein structure. This two-dimensional plot shows the allowed and disfavoured values of ψ and ϕ . For each target protein the plot indicates localization of the residues on the A chain.

2.3 Ligand drug molecules Preparations

Estimation of pharmacological properties of small molecules is considered as a crucial step towards the drug discovery. As *in vivo* estimation is time consuming and expensive, *in silico* methods have become inevitable. For *in silico* estimation, virtual screening of Drug-likeness rules (a set of guidelines for the determination of structural properties of proposed drug compounds) are used for fast calculation of drug-like properties of a molecule. Various drug-likeness rules (e.g., Lipinski's rule, MDDR-like rule, Veber's rule, Ghose filter, BBB rule, CMC-50 like rule and Quantitative Estimate of Drug-likeness (QED)) have

been used earlier in drug designing. Out of these different methods (rules), one of the dominant method is Lipinski's rule of five (RO5) which is a rule of thumb to evaluate drug-likeness or to determine if a chemical compound possesses certain pharmacological properties that would make it a potential (likely) orally active drug in humans [30]. Candidate drugs that conform to the RO5, tend to have lower attrition rates during clinical trials and hence have an increased chance of reaching the market. RO5 helps in distinguishing between drug like and non-drug like molecules by its filters which help in early preclinical development and thus helps to circumvent preclinical and clinical failures. We have done the virtual screening with various drug-likeness rules including RO5 rule, Veber's rule [31], polar surface area and number of rotatable bonds [32]. Only after these tests, the proposed drugs having required drug-likeness have been used for molecular docking simulation. Specifically, based on the positive responses from virtual screening, we selected five phytoconstituent extracted compounds from *Tinospora cordifolia* as potential reference ligand drugs: berberine ($C_{20}H_{18}NO_4$), choline ($C_5H_{14}NO$) and tetrahydropalmatine ($C_{21}H_{25}NO_4$) from the group of alkaloids, β -sitosterol ($C_{29}H_{50}O$) from steroids, octacosanol ($C_{28}H_{58}O$) from aliphatic group. Details of the structure of these molecules were downloaded from Drug Bank [33] in pdb format and are described in Table 2a-e along with various chemical and physical properties of these molecules. For docking the ligand file is required in pbdqt format. These ligand drug molecules have been saved in pbdqt format by Auto Dock Tools 1.5.6 [34].

2.4. Molecular docking and Visualization

Through molecular docking energy minimization and binding energy calculations are performed to validate the potential drug-target interactions. Through molecular docking interaction between small molecules (ligand) and protein receptor (may be an enzyme) can predict the activation or inhibition of enzyme. Molecular docking can demonstrate the feasibility of any biochemical reaction from its computational output data. It can predict an optimized orientation of ligand on its target receptor through different binding modes of ligand in the groove of target molecule and thus may provide a raw material for the rational drug designing. Molecular docking in combination with scoring function is used to evaluate large databases for finding more potent, selective and efficient drug candidates in silico. Molecular docking programs perform these tasks through a cyclical process, in which the ligand conformation is evaluated by specific scoring functions. This process is carried out recursively until converging to a solution of minimum energy [35]. Docking mechanism uses drug's binding properties to nucleic acid of target protein which establishes the correlation between drug's molecular structure and its cytotoxicity. In

this way molecular docking can predict whether the compound/drug is interacting with the protein/DNA. Molecular docking algorithms execute quantitative predictions of binding energetics, providing rankings of docked compounds based on the binding affinity of ligand-receptor complexes. The best confirmation of the ligand-receptor complexes which has lower binding energy is predicted for further analysis. After getting positive prediction, the experimental procedures are made available to find out the real binding mode of the complex which led to the development of new drug molecule.

Docking-based studies are attempted to explore the binding mode of the suggested protease inhibitors onto the 3D model of protease of CoV-2 through Receptor-ligand docking analysis and in this case it is performed using AutoDock Vina [28]. The macromolecule (protein) file is saved in pdbqt format by Auto Dock Tools [28] and ready to be used for docking. Similarly the ligand molecule has been saved in pdbqt format by Auto Dock Tools. In the AutoDock Vina algorithm for configuration file the following values of the parameters were set: (i) number of binding modes- 9; (ii) exhaustiveness of search- 8 and (iii) maximum energy difference- 3 kcal/mol. Ligand centered maps were generated and Gridbox center was set to coordinate x, y, and z of residue position of the target protein respectively. Out of all the possible poses (optimized ligand: protein complex structure) suggested by simulation according to the binding modes, the pose showing maximum hydrogen bonds and minimum binding free energy change (kcal/mol), as represented in the View window, were chosen as the best ligand:protein complex structure formed by ligand-receptor interaction. For choosing the best possible ligand:protein complex structure we have taken the help of root means square deviation (rmsd) method. Actually, rmsd values are calculated relative to the best mode and use only movable heavy atoms (ligand). Two variants are used here for the simulation. rmsd/lb (lower bound) and rmsd/ub (upper bound) differing in how the atoms are matched in the distance calculations. For the distance for upper bound is considered when the ligand has no symmetry as rmsd/ub matches each atom in a conformation with itself in the other conformation ignoring any symmetry. We have used rmsd/ub as the ligand molecules have no specific symmetry. The metabolite (ligand) making maximum number of H-bonds, hydrophobic bonds mostly show better capability to form covalent interaction and highest binding affinity with target proteins. Different output poses were analysed in Discovery Studio visualizer 2020 version 20.1.0.19295 [29] for the formation of non-bonded hydrogen bonds. The best pose structure was analysed also by other supporting hydrophobic interactions, functional groups of ligands with the amino acids of 3CL^{pro}.

3. Results and Discussion

Each expected ligand drug molecule was docked to CoV 2 3CL main protease (3CL^{PRO}). We have to keep in mind that docking algorithm is nondeterministic in nature. So for a fixed receptor:ligand pair correct conformation, the minimum of scoring function cannot be identified by docking algorithm. Table 1 shows the structure of ligand and amino acids found in the active site pockets of 3CL^{PRO} proteins I and II. Molecular docking is used to find out interaction of tested inhibitors: berberine, β -sitosterol, choline, tetrahydropalmatine and octacosanol with both 3CL^{PRO} proteins I and II. Berberine (C₂₀H₁₈NO₄) belongs to the class of organic compound known as protoberberine alkaloids and derivatives extracted from *Hydrastis canadensis* L., Berberidaceae. It is also found in many other plants. Berberine is usually found in the roots, rhizomes, stems, and bark. One of the main source of berberine is *Tinospora cordifolia*. Berberine is used as a natural dye with a color index of 75160. Due to its strong yellow fluorescence, it is useful in histology for staining heparin in mast cells. It is relatively toxic parenterally, but has been used orally for various parasitic and fungal infections and as antidiarrheal [36]. β -sitosterol (C₂₉H₅₀O) has a structural similarity with cholesterol. It is used to reduce cholesterol levels in the body. It is used as a constituents in many drugs for reduction of swelling. Being a steroid, β -sitosterol is a precursor of anabolic steroid boldenone [37]. Octacosanol (C₂₈H₅₈O) is a straight-chain aliphatic 28-carbon primary fatty alcohol that is used as a nutritional supplement. It has been studied as a potential therapeutic agent for the treatment of Parkinson's disease [38]. 1-octacosanol is reported to possess cholesterol-lowering effects, antiaggregatory properties, cytoprotective use, and ergogenic properties. Tetrahydropalmatine (C₂₁H₂₅NO₄) has a role as an adrenergic agent, a non-narcotic analgesic and a dopaminergic antagonist. Tetrahydropalmatine is under investigation in clinical trial for the Treatment of Schizophrenia [39]. Choline (C₅H₁₄NO) is a nutrient that supports various bodily functions, including cellular growth and metabolism. Choline is involved in many processes, such as cell structure and messaging, fat transport and metabolism, DNA synthesis and nervous system maintenance [40].

Candidate drugs that conform to the RO5, tend to have lower attrition rates during clinical trials and hence have an increased chance of reaching the market (Table 2a). Docking simulation was used to find out interaction of first inhibitor berberine with 3CL^{PRO} protein I (6LU7) which revealed 9 different poses based on the dock score and the pose with highest negative values of binding energy indicated maximum binding affinity (Table 3). For pose 2 we obtained the better interacted position for ligand: protein complex with the binding affinity of -7.3 kcal/mol which is lower than highly tested COVID 19 drug chloroquine (-6.29 kcal/mol). To verify that this the best docked site we have also computed the Dreiding energy of

different poses which consider the Dreiding force field to calculate the energy of a specific structure by summing energy components like bond lengths, bond angles, dihedral angles [41]. We obtained the lowest value of energy (415.725) for the same complex structure. The interaction energy further verified by the dipole moment values of ligand and target (Table 4). The strong interaction for pose 2 was further verified by the number of hydrogen bonded interactions and hydrophobic interactions present between protein and ligand in the optimized protein: ligand complex structure. Weak intermolecular interactions such as hydrogen bonding and hydrophobic interactions are key players in stabilizing energetically-favored ligands, in an open conformational environment of protein structures. It is a proven fact that hydrogen bonding and hydrophobic interactions both stabilize the ligands at the target protein site, and help alter binding affinity and drug efficacy [42]. We observed the presence of intermolecular hydrogen bonds and hydrophobic interaction between protein and berberine in its pose 2 which means better interaction between donor and acceptor moiety. We have repeated the molecular docking simulation of berberine with other 3L^{pro} protein II also and obtained the best ligand: protein complex structure with binding affinity of -7.7 kcal/mol. For best poses of berberine: protein complexes, the donor–acceptor surface and different possible interactions are shown in Figure (4a,b) in 3D and 2D view.

We have repeated same molecular docking approach for other ligand structures: β -sitosterol, octacosanol, Tetrahydropalmatine, Choline with protein I, protein II and have identified their best possible ligand:protein interaction pose position in terms of their best binding affinity value, Dreiding energy, dipole moment, hydrogen bond, hydrophobic bond etc. and mentioned them all in Table 4,5. From the molecular docking results for every suggested drug molecule, with their best possible ligand: target complex structures i.e., for best pose, the donor–acceptor surface with their possible hydrogen bonding and hydrophobic interactions are shown in Figure (5-6a,b) in 3D and 2D view. Our screening identified that out of five possible bioactive ligand structures berberine and choline show the best possible potentialities to bind with the main protease enzymes (3L^{pro}): I and II of the CoV-2. Berberine showed the best docking affinity compared to the other ligands against 3L^{pro} main protease enzyme. Berberine having less binding energy as compared to other molecules with its good binding mode of interactions. After berberine the binding affinity followed by β -sitosterol, octacosanol, Tetrahydropalmatine, Choline. Simulation results revealed that all five docking complexes showed good stability in presence of different inhibitors. These inhibitors also fulfil the required drug parameters according to RO5, MDDR, Veber rules including their molar refractivities, polarizabilities, polar surface areas and logP values. All these reported potential drug compounds are natural and also commercially available for further in vivo/in vitro

validations. The information generated from this present study may be utilized in future for the development of more phytochemical based therapeutics against COVID-19.

4. Conclusion:

Traditional Indian medicinal system has always been considered as a great source of information about the implications of various herbs and herbal formulae for the treatment of various diseases. In the present study, we have examined the antiviral potential of *Tinospora cordifolia* against SARS-CoV-2 using molecular docking approach towards discovery of novel drug-like molecules. *Tinospora cordifolia* is an Indian medicinal plant having various type of bioactive compounds including alkaloids, steroids, glycosides, aliphatics, etc. Spotlight of the present study is to find an essential drug for the COVID19 disease using the antiviral activity of these compounds. Summarizing the docking results and interpreting the interaction analysis plots with best binding docking pose of phytochemicals berberine, β -sitosterol, octacosanol, Tetrahydropalmatine, Choline from the parent herb *Tinospora cordifolia* with that of the selected 3L^{pro} targets I, II of main protease enzymes suggest the promising potential of these molecules to be used as raw drug material. Molecular docking analysis has revealed that berberine having less binding energy as compared to other molecules with its good binding mode of interactions. Simulation results have also revealed that all ten docking complexes showed stability in presence of different inhibitors. All these reported compounds are natural and also commercially available. The study provides a basic foundation and suggests that the proposed phytochemicals could serve as potential inhibitors in regulating the 3L^{pro} protein's function and controlling viral replication. Our results are expected to grab the attention of the researchers in the field of new drug discovery against SERS-CoV-2 for which no specific drugs or vaccines are available. The approach adopted here is general in nature and similar approach may be used to investigate the potential applications of other medicinal herbs and available drugs against COVID-19. In addition, the study may be extend to more precise investigation of protein-drug interaction using different quantum mechanical simulation methods like TDDFT, HF with modern tools like ONIOM which will help us to identify optimized and energetically favored drug:target-protein complex structures. However, such a task is computationally demanding and requires more computational resources and time. In a future communication, we would like to extend our work in that direction, so that if a clinical trial of the drug molecules studied here is aimed the same can be started with more confidence. Finally, we conclude this paper with a word caution that before using any outcome of an in silico study, proper in-vitro and in-vivo studies are to be performed.

Acknowledgement: Author thanks Pustak Pathak for his help in handling the simulators and software.

References:

- [1]. Droosten C, Gunther S, Preiser W, et al. Identification of a novel coronavirus in patients with severe acute respiratory syndrome. *N Engl J Med.* (2003), 348: 1967–76.
- [2]. [https://www.who.int/emergencies/diseases/novel-coronavirus-2019/technical-guidance/naming-the-coronavirus-disease-\(covid-2019\)-and-the-virus-that-causes-it](https://www.who.int/emergencies/diseases/novel-coronavirus-2019/technical-guidance/naming-the-coronavirus-disease-(covid-2019)-and-the-virus-that-causes-it) (accessed on 31 March 2020).
- [3]. Wu, F. et al. A new coronavirus associated with human respiratory disease in China. *Nature.* (2020), 579, 265–269.
- [4]. Zhou, P. et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. *Nature,* (2020) . 579, 270–273.
- [5]. Gorbalenya, A. E. et al. The species Severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2. *Nat. Microbiol* (2020), 5, 536–544.
- [6]. J. Liu, X. Liao, S. Qian et al. Community transmission of severe acute respiratory syndrome coronavirus 2, Shenzhen, China, 2020. *Emerg Infect Dis* (2020) doi.org/10.3201/eid2606.200239.
- [7]. Q. Li, X. Guan, P. Wu et al. Early transmission dynamics in Wuhan, China, of novel coronavirus-infected pneumonia. *N Engl J Med* (2020); doi:10.1056/NEJMoa2001316.
- [8]. N van Doremalen, D. Morris, T. Bushmaker et al. Aerosol and Surface Stability of SARS-CoV-2 as compared with SARS-CoV-1. *New Engl J Med* 2020 doi: 10.1056/NEJMc2004973.
- [9]. I. Aanouz, A. Belhassan, K. El-Khatibi, T. Lakhliifi, M. El-Idrissi & M. Bouachrine, Moroccan Medicinal plants as inhibitors against SARS-CoV-2 main protease: Computational Investigations, *Journal of Biomolecular Structure and Dynamics*, (2020), DOI:10.1080/07391102.2020.1758790.
- [10]. Lu H., 2020. Drug treatment options for the 2019-new coronavirus (2019-nCoV). *Biosci. Trends,* (2020), doi:10.5582/bst.01020.
- [11]. Liu, J. et al. Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro. *Cell Discovery.* (2020) 6, 1-4.
- [12]. Sukanth Kumar Enmozhi, Kavitha Raja, Irudhayasamy Sebastine & Jerrine Joseph, Andrographolide as a potential inhibitor of SARSCoV-2 main protease: an in silico approach, *Computational Investigations, Journal of Biomolecular Structure and Dynamics*, (2020), DOI: 10.1080/07391102.2020.1760136
- [13]. V.V. Sonkamble, L.H. Kamble, Antidiabetic potential and identification of phytochemicals from *Tinospora cordifolia*, *Am. J. Phytomed. Clin. Ther.* 3 (2015) 97–110.

- [14]. P. harma , B. P. Dwivedee , D.Bisht , A. K. Dash, D. Kumar; The chemical constituents and diverse pharmacological importance of *Tinospora cordifolia*, *Heliyon* 5 (2019) e02437, <https://doi.org/10.1016/j.heliyon.2019.e024>.
- [15]. BalajiAgoram , Walter S.Woltosz, Michael B.Bolger; Predicting the impact of physiological and biochemical processes on oral drug bioavailability, *Advanced Drug Delivery Reviews*, (2001) Volume 50, (1), Pages S41-S67.
- [16]. Feixiong Cheng et al, Adverse Drug Events: Database Construction and in Silico Prediction, *J. Chem. Inf. Model.* (2013), 53, 4, 744–752.
- [17]. Rana, M., & Chowdhury, P. Perturbation of hydrogen bonding in hydrated pyrrole-2-carboxaldehyde complexes. *J. Molecular Modelling* (Springer), (2017) 23, 216.
- [18]. Singla, N., & Chowdhury, P. Inclusion behaviour of Indole-7-Carboxaldehyde inside β -cyclodextrin: A nano cage. *Chemical Physics*, (2014), 441, 93-100.
- [19]. Lu, R.; Zhao, X.; Li, J.; Niu, P.; Yang, B.; Wu, H.; Wang, W.; Song, H.; Huang, B.; Zhu, N.; et al. Genomic characterisation and epidemiology of 2019 novel coronavirus: Implications for virus origins and receptor binding. *Lancet* (2020), 6736, 1–10.
- [20]. Tortorici, M.A., and Veesler, D. Structural insights into coronavirus entry. *Adv. Virus Res.* (2019) 105, 93–116.
- [21]. Walls et al., *Cell* 180, 281–292 April 16, (2020) .<https://doi.org/10.1016/j.cell.2020.02.058>.
- [22]. Fung TS, Liu DX. Human coronavirus: host-pathogen interaction. *Annu Rev Microbiol* (2019);73:529–57.
- [23]. Dayer MR, Taleb-Gassabi S, Dayer MS. Lopinavir; a potent drug against coronavirus infection: insight from molecular docking study. *Arch Clin Infect Dis* (2017);12:e13823.
- [24]. Anand K, Ziebuhr J, Wadhwani P, Mesters JR, Hilgenfeld R. Coronavirus main proteinase (3CLpro) structure: basis for design of anti-SARS drugs. *Science* (2003);300(5626):1763–7.
- [25]. Z. Jin, X. Du, Y. Xu, Y. Deng, M. Liu, Z. Zhao, et al. Structure of Mpro from COVID-19 virus and discovery of its inhibitors. *bioRxiv*. (2020).
- [26]. Mesecar, A.D. A taxonomically-driven approach to development of potent, broad-spectrum inhibitors of coronavirus main protease including SARS-CoV-2 (COVID-19). <https://www.rcsb.org/structure/6W63>. (2020) DOI: [10.2210/pdb6W63/pdb](https://doi.org/10.2210/pdb6W63/pdb)
- [27]. <https://www.rcsb.org/>
- [28]. Trott, O., & Olson, A. J. AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading. *J Comput Chem*, (2010). 31(2), 455-461. doi:10.1002/jcc.21334.
- [29]. Dassault Systèmes BIOVIA, Discovery Studio Modeling Environment, Release 2017, San Diego: Dassault Systèmes, (2016).

- [30]. Lipinski CA. "Lead- and drug-like compounds: the rule-of-five revolution". *Drug Discovery Today: Technologies*. (2004) 1 (4): 337–341.
- [31]. Veber, D. F., Johnson, S. R., Cheng, H. Y., Smith, B. R., Ward, K. W., & Kopple, K. D.. Molecular properties that influence the oral bioavailability of drug candidates. *Journal of medicinal chemistry*,(2002) 45(12), 2615-2623.
- [32]. Daina A, Michielin O, Zoete V, SwissADME: a free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules. *Sci Rep*, (2017) 7:42717. <https://doi.org/10.1038/srep42717>
- [33]. <https://www.drugbank.ca>
- [34]. Michel F. Sanner. *Python: A Programming Language for Software Integration and Development*. J. Mol. Graphics Mod., (1999), Vol 17, February. pp57-61.
- [35]. Yuriev, E.; Agostino, M.; Ramsland, P.A. Challenges and advances in computational docking: 2009 in review. *J. Mol. Recognit*. (2011), 24, 149–164.
- [36]. Dewick, P. *Medicinal Natural Products: A Biosynthetic Approach* (3rd ed.). West Sussex, England: Wiley. (2009). p. 357. [ISBN 978-0-471-49641-0](https://doi.org/10.1002/9780471496410).
- [37]. Wang Z, Guo X, Liu Z, Cui M, Song F, Liu S: Studies on alkaloids binding to GC-rich human survivin promoter DNA using positive and negative ion electrospray ionization mass spectrometry. *J Mass Spectrom*. (2008) Mar;43(3):327-35.
- [38]. Rudkowska I, AbuMweis SS, Nicolle C, Jones PJ. "Cholesterol-lowering efficacy of plant sterols in low-fat yogurt consumed as a snack or with a meal". *J Am Coll Nutr*. (2008). 27 (5): 588–95.
- [39]. Taylor, Johanna C; Rapport, Lisa; Lockwood, G.Brian "Octacosanol in human health". *Nutrition*. (2003). 19 (2): 192–5.
- [40]. Corbin KD, Zeisel SH, "Choline metabolism provides novel insights into nonalcoholic fatty liver disease and its progression". *Current Opinion in Gastroenterology*. (2012). 28 (2): 159–65.
- [41]. SL Mayo, BD Olafson, WA Goddard , DREIDING: a generic force field for molecular Simulations, . *Phys. Chem*. (1990), 94, 26, 8897–8909.
- [42]. Rohan Patil1, Suranjana Das, Ashley Stanley, Lumbani Yadav, Akulapalli Sudhakar,Ashok K. Varma, Optimized Hydrophobic Interactions and Hydrogen Bonding at the Target-Ligand Interface e Pathways of Drug-Designing, *PLoS One*. (2010); 5(8): e12029. Issue 8 | e12029.

Table 1: Configuration required of target proteins for simulation.





Protein: 3CL^{pro} (PDBID: 6W63)	Protein: 3CL^{pro} (PDBID: 6LU7)
Classification: <u>VIRAL PROTEIN/INHIBITOR</u> , main protease bound to potent broad-spectrum non-covalent inhibitor X77	Classification: <u>VIRAL PROTEIN</u> , main protease in complex with an inhibitor N3
Organism(s): <u>Severe acute respiratory syndrome coronavirus 2</u>	Organism(s): <u>Severe acute respiratory syndrome coronavirus 2, synthetic construct</u>
Molecule: 3C-like proteinase, Mutation(s): 0	Molecule: main protease Mutation(s): 0
Chains: A SequenceLength: 306 Gene Names: <u>rep, 1a-1b</u>	Chains: A SequenceLength: 306 GeneNames: <u>rep, 1a-1b</u>
X-RAY DIFFRACTION DATA Resolution: 2.10 Å R-Value Free: 0.221 R-Value Work: 0.150 R-Value Observed: 0.157 Space Group: <u>P 2₁ 2₁ 2</u>	X-RAY DIFFRACTION DATA Resolution: 2.16 Å R-Value Free: 0.235 R-Value Work: 0.202 R-Value Observed: 0.204 Space Group: <u>C 1 2 1</u>
Length (Å) Angle (°) a = 45.05 α = 90 b = 63.84 β = 90 c = 106.588 γ = 90	Length (Å) Angle (°) a = 97.931 α = 90 b = 79.477 β = 114.55 c = 51.803 γ = 90
Macromolecule Content Total Structure Weight: 34.29 kDa Atom Count: 4995 Residue Count: 305 Unique protein chains: 1	Macromolecule Content Total Structure Weight: 34.51 kDa Atom Count: 2500 Residue Count: 312 Unique protein chains: 2
	
 Native ligand	 Native ligand
C₂₇ H₃₃ N₅ O₂	

Table 2(a-e): Molecular configuration of ligand drug molecules

a. Ligand: berberine (C₂₀H₁₈NO₄)	
Property	Value
Mass	336.3612
Chemical Formula	C ₂₀ H ₁₈ NO ₄
Toxicity and Affected organisms	Not available
State	Solid
melting point (°C)	145 °C
water solubility	0.000354 mg/mL
Lipophilicity (logP)	-1.3
Hydrogen Acceptor Count	4
Hydrogen Donor Count	0
Polar Surface Area	40.8 Å ²
Rule of Five	Yes
Bioavailability	1
Number of Rings	5
Refractivity	93.52 m ³ ·mol ⁻¹
Polarizability	36.92 Å ³

b. Ligand: β-sitosterol (C₂₉H₅₀O)	
Property	Value
Mass	414.718
Chemical Formula	C ₂₉ H ₅₀ O
Toxicity and Affected organisms	Not Available
State	Solid
melting point (°C)	Not Available
water solubility	1.84e-05 mg/mL
logP	7.27
Hydrogen Acceptor Count	1
Hydrogen Donor Count	1
Polar Surface Area	20.23 Å ²
Rule of Five	Partly yes
Bioavailability	1
Number of Rings	4
Refractivity	129.77 m ³ ·mol ⁻¹
Polarizability	54.21 Å ³

c. Ligand: choline (C₅H₁₄NO)	
Property	Value
Mass	104.17
Chemical Formula	C ₅ H ₁₄ NO
Toxicity and Affected organisms	Oral rat LD ₅₀ : 3400 mg/kg, Humans and other mammals
State	Liquid
melting point (°C)	244-247 °C (as chloride salt)
water solubility	3.61 mg/mL
logP	-3.6
Hydrogen Acceptor Count	1
Hydrogen Donor Count	1
Polar Surface Area	20.23 Å ²
Rule of Five	Yes
Bioavailability	1
Number of Rings	0
Refractivity	42.19 m ³ ·mol ⁻¹
Polarizability	12.57 Å ³

d. Ligand: octacosanol (C₂₈H₅₈O)		e. Ligand: tetrahydropalmatine (C₂₁H₂₅NO₄)	
Property	Value	Property	Value
Mass	410.7595	Mass	355.434
Chemical Formula	C ₂₈ H ₅₈ O	Chemical Formula	C ₂₁ H ₂₅ NO ₄
Toxicity and Affected organisms	Not Available	Toxicity and Affected organisms	Not available
State	Not Available	State	Not available
melting point (°C)	Not Available	melting point (°C)	Not available
water solubility	(1.25e-05 mg/mL)	water solubility	(0.0246 mg/mL)
logP	10.25	logP	3.15
Hydrogen Acceptor Count	1	Hydrogen Acceptor Count	5
Hydrogen Donor Count	1	Hydrogen Donor Count	0
Polar Surface Area	20.23 Å ²	Polar Surface Area	40.16 Å ²
Rule of Five	Partly yes	Rule of Five	Yes
Bioavailability	0	Bioavailability	1
Number of Rings	0	Number of Rings	4
Refractivity	132.56 m ³ ·mol ⁻¹	Refractivity	101.36 m ³ ·mol ⁻¹
Polarizability	60.17 Å ³	Polarizability	39.97 Å ³

Table 3. Binding mode of each ligand:protein (Berberine: 6LU7) complex using molecular docking for Protein (I).

Pose	Binding affinity	Hydrogen bonded interaction	Drieding energy (ligand)	Drieding energy (protein)	Dipolemoment of ligand(debye)
1	-7.3	0	414.419	6,044.79	1.676
2	-7.3	2	415.725	6,045.91	1.677
3	-7.1	0	412.076	6,042.69	1.675
4	-7.0	0	414.361	6,044.95	1.68
5	-7.0	0	415.549	6,045.57	1.672
6	-6.9	0	414.623	6,044.94	1.676
7	-6.9	0	414.409	6,044.77	1.68
8	-6.9	0	415.07	6,046.38	1.68
9	-6.8	0	415.635	6,046.05	1.675

Table 4: Interaction detail for different ligands with protein I (6LU7)

Ligand	Best Binding affinity (kcal/mole)	Hydrogen bonded interaction (protein donor: ligand acceptor, distance in Å)	Hydrophobic interaction (protein donor: ligand acceptor, distance in Å)	Dipole moment of ligand (debye)	Drying energy between protein and ligand
Berberine	-7.3	(A:GLU166: - :UNK0:O, 3.03944) (A:THR25:HG1 - :UNK0, 2.98163)	(:UNK0- :CYS145, 5.4935)	1.67	415.725
β-sitosterol	-7.1	(:UNK0:O - A:ARG188:O, 3.12606)	(:MET165 -:UNK0, 4.54304)	1.761	1280.56
Choline	-3.4	(:UNK0:O - A:TYR54:OH, 2.8027) (:UNK0:C - A:MET49:O, 3.71379) (:UNK0:C- A:GLN189:OE1, 3.61393)	(:UNK0:C - A:HIS41, 3.8048)	5.374	104.198
Tetrahydro palmatine	-6.4		(:UNK0:C - A:MET165, 4.73002) (:UNK0:C - A:LEU167, 4.89871) (:UNK0:C - A:PRO168, 5.01258) (:UNK0 - A:CYS145, 5.27402) (:UNK0 - A:MET165, 4.58548)	2.688	373.677
octacosanol	-6.6	(:UNK0:O - A:LEU141:O, 3.37559) (:UNK0:C - A:HIS163:NE2, 3.62548)	(:UNK0 - A:ALA191, 4.8791)	1.257	414.094

Table 5: Interaction detail for different ligands with protein II (6W63)

Ligand	Best Binding affinity (kcal/mole)	Hydrogen bonded interaction (protein donor: ligand acceptor, distance in Å)	Hydrophobic interaction (protein donor: ligand acceptor, distance in Å)	Dipole moment (debye)	Drying energy between protein and ligand
Berberine	-7.7	(A:THR24:HG1 - :UNK0:O, 2.9335)	A:HIS41 - :UNK0, 3.86746 A:HIS41 - :UNK0, 3.85981 :UNK0 - A:CYS145, 5.40468	1.677	426.855
β-sitosterol	-8.0		A:CYS44 - :UNK0, 5.02829 A:MET49 - :UNK0, 4.7919 A:MET165 - :UNK0, 4.24509 :UNK0:C - A:MET165, 4.39444 A:HIS41 - :UNK0, 4.30937	1.473	1,284.01
Choline	-3.3		:UNK0:C - A:HIS41, 3.6805 :UNK0:C - A:HIS41, 3.91798	4.177	103.961

Tetrahydrop almatine	-6.4	:UNK0:C - A:MET49:O, 3.53709	A:HIS41 - :UNK0, 3.70768 A:THR24:C,O;THR25:N - :UNK0, 5.01159	2.669	373.597
octacosanol	-8.1	A:ASN119:HD21 - :UNK0:O, 2.1903	A:THR25:CG2 - :UNK0, 3.80725 A:HIS41 - :UNK0, 4.09107 A:HIS41 - :UNK0, 4.46232 A:HIS41 - :UNK0, 5.27182 :UNK0 - A:CYS44, 5.37368 :UNK0 - A:MET49, 5.27559 :UNK0 - A:MET49, 5.22475	1.253	414.219

Figure 1: Morphology of *Tinospora cordifolia*



Leaf of *Tinospora cordifolia*



Stem of *Tinospora cordifolia*

Figure 2: Different phytoconstituent extracted compounds from Guduchi Pippali (Giloy) or *Tinospora cordifolia* as ligand molecules.




Figure 3a,b: Different phytoconstituent extracted compounds from Guduchi Pippali (Giloy) or *Tinospora cordifolia* as ligand molecules.




Figure 4a,b: Donor: acceptor surface and possible types of interactions in best pose structure obtained from molecular docking for berberine: 6LU7 and berberine: 6W63





Figure 5. Donor: acceptor surface and possible types of interactions in best pose structures obtained from molecular docking for different ligands with COVID-19 protease enzyme 3CL^{pro} (6LU7).









Figure 6. Donor: acceptor surface and possible types of interactions in best pose structures obtained from molecular docking for different ligands with COVID-19 protease enzyme 3CL^{pro} (6W63).







3D: octacosanol:6W63




2D: octacosanol: 6W63




3D: tetrahydropalmatine:6W63



2D: tetrahydropalmatine: 6W63



3D: β -sitosterol:6W63



2D: β -sitosterol: 6W63